Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650338 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Santen.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT00650338 is a Phase 2 study that has completed, run by Santen. The registered enrollment target is 165 participants.
The verdict
NCT00650338, a Phase 2 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
Interventions
- DRUG Placebo
- DRUG 0.005% latanoprost
- DRUG DE-104 ophthalmic solution, low concentration
- DRUG DE-104 ophthalmic solution, medium concentration
- DRUG DE-104 ophthalmic solution, high concentration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650338
The ClinicalTrials.gov registry entry for NCT00650338 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00650338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650338 about?
NCT00650338 is a clinical study titled "Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension". To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
What is the current status of trial NCT00650338?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2008-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00650338?
The interventions under investigation include: Placebo (DRUG), 0.005% latanoprost (DRUG), DE-104 ophthalmic solution, low concentration (DRUG), DE-104 ophthalmic solution, medium concentration (DRUG), DE-104 ophthalmic solution, high concentration (DRUG).
Who is sponsoring clinical trial NCT00650338?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.